For US Residents Only

Prescribing Information


Home > For Healthcare Professionals

CYSTARAN Reduces Corneal Cystine Crystals1,2

Cystine crystals are an ocular effect of cystinosis. Corneal cystine crystal accumulation may lead to painful and debilitating complications in patients with cystinosis, including2-4:

  • Photophobia
  • Eye pain
  • Squinting
  • Band keratopathy
  • Foreign body sensation
  • Corneal haziness
  • Blepharospasm
  • Corneal abrasion

Only ophthalmic cysteamine therapy has been proven to reduce corneal cystine crystals. Oral cysteamine therapy is ineffective in reducing the ocular effects of cystinosis.1-3

For information about CYSTARAN, or to place an order, please call: 1‑877‑534‑9627.
For medical information about CYSTARAN, please call: 1‑866‑634‑2765.

References: 1. CYSTARAN [prescribing information]. Gaithersburg, MD: Leadiant Biosciences, Inc.; 2012. 2. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab. 2000;71:100-120. 3. Kaiser-Kupfer MI, Fujikawa L, Kuwabara T, Jain S, Gahl WA. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl J Med. 1987;316:775-779. 4. Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol. 2007;52:97-105.


CYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

Important Safety Information:

The most frequently reported ocular adverse reactions occurring in ≥10% of patients were sensitivity to light, redness, eye pain/irritation, headache, and visual field defects.